Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Malignant Melanoma

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 127 articles:
HTML format



Single Articles


    November 2020
  1. JOHANNET P, Coudray N, Donnelly DM, Jour G, et al
    Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.
    Clin Cancer Res. 2020 Nov 18. pii: 1078-0432.CCR-20-2415.
    PubMed     Abstract available


  2. MUELLER KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, et al
    Neoadjuvant Therapy for Melanoma: A US Food and Drug Administration - Melanoma Research Alliance Public Workshop.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3285.
    PubMed     Abstract available


  3. SALAMA AKS, Palta M, Rushing CN, Selim MA, et al
    Ipilimumab and Radiation in Patients with High Risk Resected or Regionally Advanced Melanoma.
    Clin Cancer Res. 2020 Nov 10. pii: 1078-0432.CCR-20-2452.
    PubMed     Abstract available


    October 2020
  4. GANDHI S, Pandey MR, Attwood K, Ji W, et al
    Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
    Clin Cancer Res. 2020 Oct 30. pii: 1078-0432.CCR-20-2381.
    PubMed     Abstract available


  5. FANE ME, Ecker BL, Kaur A, Marino GE, et al
    sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-0446.
    PubMed     Abstract available


  6. MARSAVELA G, Lee J, Calapre L, Wong SQ, et al
    Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
    Clin Cancer Res. 2020 Oct 16. pii: 1078-0432.CCR-20-2251.
    PubMed     Abstract available


  7. CHUA V, Mattei J, Han A, Johnston L, et al
    The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
    Clin Cancer Res. 2020 Oct 15. pii: 1078-0432.CCR-20-2536.
    PubMed     Abstract available


    September 2020
  8. TANG B, Chi Z, Chen Y, Liu X, et al
    Correction: Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
    Clin Cancer Res. 2020;26:5048.
    PubMed    


  9. TRUONG A, Yoo JH, Scherzer M, Sanchez JMS, et al
    Chloroquine sensitizes GNAQ/11-mutated melanoma to MEK1/2 inhibition.
    Clin Cancer Res. 2020 Sep 15. pii: 1078-0432.CCR-20-1675.
    PubMed     Abstract available


    August 2020
  10. MARUSAK C, Thakur V, Li Y, Freitas JT, et al
    Targeting Extracellular Matrix Remodeling restores BRAF Inhibitor Sensitivity in BRAFi Resistant Melanoma.
    Clin Cancer Res. 2020 Aug 20. pii: 1078-0432.CCR-19-2773.
    PubMed     Abstract available


  11. MIDDLETON MR, McAlpine C, Woodcock VK, Corrie P, et al
    Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma.
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-1247.
    PubMed     Abstract available


    June 2020
  12. CARLINO MS, Menzies AM, Atkinson VG, Cebon JS, et al
    Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B.
    Clin Cancer Res. 2020 Jun 30. pii: 1078-0432.CCR-20-0177.
    PubMed     Abstract available


  13. CHAUVIN JM, Ka M, Pagliano O, Menna C, et al
    IL-15 stimulation with TIGIT blockade reverses CD155-mediated NK cell dysfunction in melanoma.
    Clin Cancer Res. 2020 Jun 26. pii: 1078-0432.CCR-20-0575.
    PubMed     Abstract available


  14. SHOUSHTARI AN, Bao R, Luke JJ
    PD-1 Blockade in Chinese versus Western Patients with Melanoma.
    Clin Cancer Res. 2020 Jun 2. pii: 1078-0432.CCR-20-1558.
    PubMed     Abstract available


    May 2020
  15. HAMID O, Bruno R, Fasso M, O'Hear C, et al
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Response.
    Clin Cancer Res. 2020;26:2436.
    PubMed    


  16. GOLDSTEIN DA, Ratain MJ
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
    Clin Cancer Res. 2020;26:2435.
    PubMed    


  17. ALGAZI AP, Twitty CG, Tsai KK, Le M, et al
    Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
    Clin Cancer Res. 2020 May 6. pii: 1078-0432.CCR-19-2217.
    PubMed     Abstract available


    April 2020
  18. LEPLETIER A, Madore J, O'Donnell JS, Johnston RL, et al
    Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma.
    Clin Cancer Res. 2020 Apr 28. pii: 1078-0432.CCR-19-3925.
    PubMed     Abstract available


  19. LEE JH, Menzies AM, Carlino MS, McEvoy AC, et al
    Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3926.
    PubMed     Abstract available


  20. TANG B, Chi Z, Chen YB, Liu X, et al
    Safety, Efficacy and Biomarker Analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial.
    Clin Cancer Res. 2020 Apr 22. pii: 1078-0432.CCR-19-3922.
    PubMed     Abstract available


  21. BASLER L, Gabrys HS, Hogan SA, Pavic M, et al
    Radiomics, tumor volume and blood biomarkers for early prediction of pseudoprogression in metastatic melanoma patients treated with immune checkpoint inhibition.
    Clin Cancer Res. 2020 Apr 6. pii: 1078-0432.CCR-20-0020.
    PubMed     Abstract available


  22. ICHIKAWA J, Yoshida T, Isser A, Laino AS, et al
    Rapid Expansion of Highly Functional Antigen-Specific T cells from Melanoma Patients by Nanoscale Artificial Antigen Presenting Cells.
    Clin Cancer Res. 2020 Apr 2. pii: 1078-0432.CCR-19-3487.
    PubMed     Abstract available


    March 2020
  23. SHATTUCK-BRANDT RL, Chen SC, Murray E, Johnson CA, et al
    Metastatic Melanoma Patient-derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Clin Cancer Res. 2020 Mar 31. pii: 1078-0432.CCR-19-1895.
    PubMed     Abstract available


  24. POSTOW MA, Knox SJ, Goldman DA, Elhanati Y, et al
    A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
    Clin Cancer Res. 2020 Mar 23. pii: 1078-0432.CCR-19-3936.
    PubMed     Abstract available


  25. YANG RK, Kuznetsov IB, Ranheim EA, Wei JS, et al
    Outcome-related signatures identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated After Starting Hu14.18-IL2.
    Clin Cancer Res. 2020 Mar 9. pii: 1078-0432.CCR-19-3294.
    PubMed     Abstract available


    February 2020
  26. WATANABE T, Gaedicke S, Guffart E, Firat E, et al
    Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8(+) T-Cell-Dependent Tumor Activity.
    Clin Cancer Res. 2020;26:945-956.
    PubMed     Abstract available


  27. LI C, Guo W, Ma J, Yang Y, et al
    ATP-citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-1359.
    PubMed     Abstract available


  28. LUCCI A, Hall C, Patel SP, Narendran B, et al
    Circulating tumor cells and early relapse in node-positive melanoma.
    Clin Cancer Res. 2020 Feb 3. pii: 1078-0432.CCR-19-2670.
    PubMed     Abstract available


    January 2020
  29. VERHEIJDEN RJ, May AM, Blank CU, Aarts MJB, et al
    Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry.
    Clin Cancer Res. 2020 Jan 27. pii: 1078-0432.CCR-19-3322.
    PubMed     Abstract available


  30. SMALLEY I, Law V, Wyatt C, Evernden B, et al
    Proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and therapeutic resistance.
    Clin Cancer Res. 2020 Jan 10. pii: 1078-0432.CCR-19-2840.
    PubMed     Abstract available


    November 2019
  31. RIBAS A, Daud A, Pavlick AC, Gonzalez R, et al
    Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-4180.
    PubMed     Abstract available


  32. DIZIER B, Callegaro A, Debois M, Dreno B, et al
    A T-helper 1/interferon- gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-3717.
    PubMed     Abstract available


    October 2019
  33. KULKARNI PM, Robinson EJ, Sarin Pradhan J, Gartrell-Corrado RD, et al
    Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death.
    Clin Cancer Res. 2019 Oct 21. pii: 1078-0432.CCR-19-1495.
    PubMed     Abstract available


    September 2019
  34. NAMIKAWA K, Aung PP, Milton DR, Tetzlaff MT, et al
    Correlation of tumor burden in sentinel lymph nodes with tumor burden in non-sentinel lymph nodes and survival in cutaneous melanoma.
    Clin Cancer Res. 2019 Sep 30. pii: 1078-0432.CCR-19-1194.
    PubMed     Abstract available


  35. LUKE JJ, Olson DJ, Allred JB, Strand CA, et al
    Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201).
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-19-1223.
    PubMed     Abstract available


  36. DI GIACOMO AM, Covre A, Finotello F, Rieder D, et al
    Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial.
    Clin Cancer Res. 2019 Sep 17. pii: 1078-0432.CCR-19-1335.
    PubMed     Abstract available


  37. THAKUR R, Laye JP, Lauss M, Diaz JMS, et al
    Transcriptomic analysis reveals prognostic molecular signatures of stage I melanoma.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-18-3659.
    PubMed     Abstract available


  38. EDWARDS J, Batten M, Ferguson A, Palendira U, et al
    Novel Immune Targets in Melanoma-Response.
    Clin Cancer Res. 2019;25:5424-5425.
    PubMed    


  39. NOCENTINI G, Cari L, Riccardi C
    Novel Immune Targets in Melanoma-Letter.
    Clin Cancer Res. 2019;25:5422-5423.
    PubMed    


    August 2019
  40. JIANG H, Shin DH, Nguyen TT, Fueyo J, et al
    Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
    Clin Cancer Res. 2019 Aug 27. pii: 1078-0432.CCR-19-0405.
    PubMed     Abstract available


  41. VASHISHT GOPAL YN, Gammon ST, Prasad R, Knighton B, et al
    A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor-resistance in melanoma.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0836.
    PubMed     Abstract available


  42. ALOIA A, Mullhaupt D, Chabbert CD, Eberhart T, et al
    A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0253.
    PubMed     Abstract available


  43. KONG Y, Yu J, Yan J, Guo Q, et al
    Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-19-0475.
    PubMed     Abstract available


  44. PENG W, Williams LJ, Xu C, Melendez B, et al
    Anti-OX40 antibody directly enhances the function of tumor-reactive CD8(+) T cells and synergizes with PI3Kbeta inhibition in PTEN loss melanoma.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-1259.
    PubMed     Abstract available


    July 2019
  45. HAMID O, Molinero L, Bolen CR, Sosman JA, et al
    Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab.
    Clin Cancer Res. 2019 Jul 29. pii: 1078-0432.CCR-18-3488.
    PubMed     Abstract available


  46. FIELD MG, Kuznetsov JN, Bussies PL, Cai L, et al
    BAP1 loss is associated with DNA methylomic repatterning in highly aggressive Class 2 uveal melanomas.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-0366.
    PubMed     Abstract available


    June 2019
  47. FAIAO-FLORES F, Emmons MF, Durante MA, Kinose F, et al
    HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3382.
    PubMed     Abstract available


  48. ANBUNATHAN H, Verstraten R, Singh AD, Harbour JW, et al
    Integrative copy number analysis of uveal melanoma reveals novel candidate genes involved in tumorigenesis including a tumor suppressor role for PHF10/BAF45a.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-18-3052.
    PubMed     Abstract available


  49. RODRIGUES M, Mobuchon L, Houy A, Alsafadi S, et al
    Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations.
    Clin Cancer Res. 2019 Jun 21. pii: 1078-0432.CCR-19-1215.
    PubMed     Abstract available


  50. TOKI MI, Merritt CR, Wong PF, Smithy JW, et al
    High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling.
    Clin Cancer Res. 2019 Jun 12. pii: 1078-0432.CCR-19-0104.
    PubMed     Abstract available


    May 2019
  51. LUKE JJ, Bao R, Sweis RF, Spranger S, et al
    WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
    Clin Cancer Res. 2019;25:3074-3083.
    PubMed     Abstract available


  52. GOFF SL, Rosenberg SA
    BRAF Inhibition: Bridge or Boost to T-cell Therapy?
    Clin Cancer Res. 2019;25:2682-2684.
    PubMed     Abstract available


    April 2019
  53. COHEN JV, Sullivan RJ
    Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-0836.
    PubMed     Abstract available


  54. SHOUSHTARI AN
    About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-19-0658.
    PubMed     Abstract available


  55. WU RY, Kong PF, Xia L, Huang Y, et al
    Regorafenib promotes anti-tumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma.
    Clin Cancer Res. 2019 Apr 2. pii: 1078-0432.CCR-18-2840.
    PubMed     Abstract available


    March 2019
  56. WEISS SA, Wolchok JD, Sznol M
    Immunotherapy of melanoma: facts and hopes.
    Clin Cancer Res. 2019 Mar 28. pii: 1078-0432.CCR-18-1550.
    PubMed     Abstract available


  57. YAN Y, Wongchenko MJ, Robert C, Larkin J, et al
    Genomic features of exceptional response in vemurafenib +/- cobimetinib-treated patients with BRAFV600-mutated metastatic melanoma.
    Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-0720.
    PubMed     Abstract available


  58. JOHNSON DB, Balko JM
    Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?
    Clin Cancer Res. 2019;25:1452-1454.
    PubMed     Abstract available


    February 2019
  59. ZHOU R, Shi C, Tao W, Li J, et al
    Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations.
    Clin Cancer Res. 2019 Feb 19. pii: 1078-0432.CCR-18-3442.
    PubMed     Abstract available


  60. EDWARDS JJ, Tasker A, Silva I, Quek C, et al
    Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma: implications for clinical trials.
    Clin Cancer Res. 2019 Feb 18. pii: 1078-0432.CCR-18-4011.
    PubMed     Abstract available


  61. ATAY C, Kwak T, Lavilla-Alonso S, Donthireddy L, et al
    BRAF targeting sensitizes resistant melanoma to cytotoxic T cells.
    Clin Cancer Res. 2019 Feb 14. pii: 1078-0432.CCR-18-2725.
    PubMed     Abstract available


    January 2019
  62. GARTRELL RD, Marks DK, Rizk EM, Bogardus M, et al
    Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
    Clin Cancer Res. 2019 Jan 15. pii: 1078-0432.CCR-18-2847.
    PubMed     Abstract available


  63. PIRES DA SILVA I, Wang KYX, Wilmott JS, Holst J, et al
    Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
    Clin Cancer Res. 2019 Jan 10. pii: 1078-0432.CCR-18-1680.
    PubMed     Abstract available


  64. WONG PF, Wei W, Smithy JW, Acs B, et al
    Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma.
    Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2652.
    PubMed     Abstract available


    December 2018
  65. VAN MEIR EG, Dong L, You S, Zhang Q, et al
    Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1368.
    PubMed     Abstract available


  66. KIM SH, Roszik J, Cho SN, Ogata D, et al
    The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma.
    Clin Cancer Res. 2018 Dec 11. pii: 1078-0432.CCR-18-1163.
    PubMed     Abstract available


  67. JOSEPH RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, et al
    Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
    Clin Cancer Res. 2018;24:6098.
    PubMed    


    November 2018
  68. TARHINI AA, Lee SJ, Li X, Rao UN, et al
    E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-alpha2b in Advanced Melanoma.
    Clin Cancer Res. 2018 Nov 12. pii: 1078-0432.CCR-18-2258.
    PubMed     Abstract available


  69. LIM SY, Lee JH, Gide TN, Menzies AM, et al
    Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.
    Clin Cancer Res. 2018 Nov 8. pii: 1078-0432.CCR-18-2795.
    PubMed     Abstract available


    August 2018
  70. WOODS D, Ramakrishnan R, Laino AS, Berglund AE, et al
    Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T-cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-1100.
    PubMed     Abstract available


  71. GOTTESDIENER LS, O'Connor S, Busam KJ, Won H, et al
    Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-1397.
    PubMed     Abstract available


    July 2018
  72. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    PubMed     Abstract available


  73. JOHNSON DB, Dahlman KB
    Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition.
    Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1795.
    PubMed     Abstract available


  74. JOHNSON DB, Bordeaux JM, Kim JY, Vaupel CA, et al
    Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0309.
    PubMed     Abstract available


    June 2018
  75. PAWELEC G
    Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma?
    Clin Cancer Res. 2018 Jun 15. pii: 1078-0432.CCR-18-1475.
    PubMed     Abstract available


  76. DANKNER M, Lajoie M, Moldoveanu D, Nguyen TT, et al
    Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-17-3384.
    PubMed     Abstract available


  77. WARNER AB, Postow MA
    Bigger is not always better: Tumor size and prognosis in advanced melanoma.
    Clin Cancer Res. 2018 Jun 14. pii: 1078-0432.CCR-18-1311.
    PubMed     Abstract available


    May 2018
  78. FORGET MA, Haymaker C, Hess KR, Meng YJ, et al
    Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome.
    Clin Cancer Res. 2018 May 30. pii: 1078-0432.CCR-17-3649.
    PubMed     Abstract available


  79. BEZROOKOVE V, Nosrati M, Miller JR, de Semir D, et al
    Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.
    Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0791.
    PubMed     Abstract available


  80. TEH JLF, Aplin AE
    Playing the melanoma endgame.
    Clin Cancer Res. 2018 May 16. pii: 1078-0432.CCR-18-0989.
    PubMed     Abstract available


    April 2018
  81. JOSEPH RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, et al
    Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-2386.
    PubMed     Abstract available


  82. EROGLU Z, Chen YA, Gibney GT, Weber JS, et al
    Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma.
    Clin Cancer Res. 2018 Apr 19. pii: 1078-0432.CCR-18-0565.
    PubMed     Abstract available


  83. SANLORENZO M, Vujic I, Floris A, Novelli M, et al
    BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-17-1914.
    PubMed     Abstract available


  84. YANG J, Hamid O, Carvajal RD
    The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.
    Clin Cancer Res. 2018 Apr 2. pii: 1078-0432.CCR-18-0020.
    PubMed     Abstract available


    March 2018
  85. EDWARDS J, Wilmott JS, Madore J, Gide TN, et al
    CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and expand significantly during anti-PD1 treatment.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2257.
    PubMed     Abstract available


  86. ZHANG G, Wu LW, Mender I, Barzily-Rokni M, et al
    Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
    Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2773.
    PubMed     Abstract available


  87. OO ZY, Stevenson AJ, Proctor MA, Daignault SM, et al
    Endogenous replication stress marks melanomas sensitive to CHK1 inhibitors in vivo.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2701.
    PubMed     Abstract available


    January 2018
  88. ATKINS MB, Hodi FS, Thompson JA, McDermott D, et al
    Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study.
    Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3436.
    PubMed     Abstract available


  89. MARSHALL JF
    Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
    Clin Cancer Res. 2018;24:253-255.
    PubMed     Abstract available


    December 2017
  90. JIN Y, Zhang P, Wang Y, Jin B, et al
    Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma.
    Clin Cancer Res. 2017 Dec 12. pii: 1078-0432.CCR-17-1703.
    PubMed     Abstract available


    November 2017
  91. GIDE TN, Wilmott JS, Scolyer RA, Long GV, et al
    Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
    Clin Cancer Res. 2017 Nov 10. pii: clincanres.2267.2017.
    PubMed     Abstract available


    October 2017
  92. KOSTER BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, et al
    Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
    Clin Cancer Res. 2017;23:5679-5686.
    PubMed     Abstract available


    September 2017
  93. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Abstract available


    August 2017
  94. ENNEN M, Keime C, Gambi G, Kieny A, et al
    MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra and inter-tumoral heterogeneity of primary melanoma.
    Clin Cancer Res. 2017 Aug 28. pii: clincanres.0010.2017.
    PubMed     Abstract available


  95. KONG Y, Sheng X, Wu X, Yan J, et al
    Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma indicate the potential for CDK4/6 Inhibitors in Targeted Therapy.
    Clin Cancer Res. 2017 Aug 22. pii: clincanres.0070.2017.
    PubMed     Abstract available


  96. KASHANI-SABET M, Nosrati M, Miller J, Sagebiel R, et al
    Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.1317.2017.
    PubMed     Abstract available


    July 2017
  97. NIESSNER H, Sinnberg T, Kosnopfel C, Smalley KSM, et al
    BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.0098.2017.
    PubMed     Abstract available


  98. KAKAVAND H, Rawson RV, Pupo GM, Yang JYH, et al
    PD-L1 expression and immune escape in melanoma resistanceto MAPK inhibitors.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.1688.2016.
    PubMed     Abstract available


  99. BAI X, Kong Y, Chi Z, Sheng X, et al
    MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients a retrospective study of 2793 cases.
    Clin Cancer Res. 2017 Jul 18. pii: clincanres.0980.2017.
    PubMed     Abstract available


    June 2017
  100. DELORD JP, Robert C, Nyakas M, McArthur GA, et al
    Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.2923.2016.
    PubMed     Abstract available


  101. NISHINO M, Giobbie-Hurder A, Manos MP, Bailey N, et al
    Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
    Clin Cancer Res. 2017 Jun 7. doi: 10.1158/1078-0432.CCR-17-0114.
    PubMed     Abstract available


    May 2017
  102. KULKARNI A, Al-Hraishawi H, Simhadri S, Hirshfield KM, et al
    BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V600E mutant melanoma.
    Clin Cancer Res. 2017 May 24. pii: clincanres.0758.2016.
    PubMed     Abstract available


  103. BUTTERFIELD LH, Zhao F, Lee S, Tarhini AA, et al
    Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697).
    Clin Cancer Res. 2017 May 23. pii: clincanres.3016.2016.
    PubMed     Abstract available


  104. WONGCHENKO MJ, McArthur GA, Dreno B, Larkin J, et al
    Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups With Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.
    Clin Cancer Res. 2017 May 23. pii: clincanres.0172.2017.
    PubMed     Abstract available


  105. VILAIN RE, Menzies AM, Wilmott JS, Kakavand H, et al
    Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma.
    Clin Cancer Res. 2017 May 16. pii: clincanres.0698.2016.
    PubMed     Abstract available


  106. PARKHURST M, Gros A, Pasetto A, Prickett T, et al
    Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Clin Cancer Res. 2017;23:2491-2505.
    PubMed     Abstract available


  107. INFANTE JR, Hollebecque A, Postel-Vinay S, Bauer TM, et al
    Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
    Clin Cancer Res. 2017;23:2423-2432.
    PubMed     Abstract available


    April 2017
  108. FRIEDMAN AA, Xia Y, Trippa L, Le LP, et al
    Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.3029.2016.
    PubMed     Abstract available


  109. SUNSHINE JC, Nguyen P, Kaunitz G, Cottrell T, et al
    PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
    Clin Cancer Res. 2017 Apr 20. pii: clincanres.1821.2016.
    PubMed     Abstract available


  110. SEGAL NH, Logan TF, Hodi FS, McDermott D, et al
    Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
    Clin Cancer Res. 2017;23:1929-1936.
    PubMed     Abstract available


  111. IIDA Y, Ciechanover A, Marzese DM, Hata K, et al
    Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-kappaB Pathway in Melanoma.
    Clin Cancer Res. 2017 Apr 7. pii: clincanres.0146.2017.
    PubMed     Abstract available


    March 2017

  112. Correction: PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
    Clin Cancer Res. 2017;23:1361.
    PubMed    


    February 2017
  113. CHUK MK, Chang JT, Theoret MR, Sampene E, et al
    FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 24. pii: clincanres.0663.2016.
    PubMed     Abstract available


  114. BEHERA R, Kaur A, Webster MR, Kim S, et al
    Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho.
    Clin Cancer Res. 2017 Feb 23. pii: clincanres.0201.2017.
    PubMed     Abstract available


  115. EXLEY MA, Friedlander P, Alatrakchi N, Vriend L, et al
    Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: a Phase 1 Clinical Trial.
    Clin Cancer Res. 2017 Feb 13. pii: clincanres.0600.2016.
    PubMed     Abstract available


  116. BARONE A, Hazarika M, Theoret MR, Mishra-Kalyani P, et al
    FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Feb 8. pii: clincanres.0664.2016.
    PubMed     Abstract available


    January 2017
  117. DENIGER DC, Kwong ML, Pasetto A, Dudley ME, et al
    A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2017;23:351-362.
    PubMed     Abstract available


  118. HAZARIKA M, Chuk MK, Theoret MR, Mushti S, et al
    U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.0712.2016.
    PubMed     Abstract available


  119. BEAVER JA, Theoret MR, Mushti S, He K, et al
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.0714.2016.
    PubMed     Abstract available


    November 2016
  120. GANNON P, Baumgaertner P, Huber A, Iancu EM, et al
    Rapid and continued T cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients.
    Clin Cancer Res. 2016 Nov 21. pii: clincanres.1708.2016.
    PubMed     Abstract available


  121. NAGARAJAN P, Curry JL, Ning J, Piao J, et al
    Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases.
    Clin Cancer Res. 2016 Nov 18. pii: clincanres.2126.2016.
    PubMed     Abstract available


  122. SANGIOLO D, Gammaitoni L, Giraudo L, Macagno M, et al
    Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1524.2016.
    PubMed     Abstract available


  123. KHALIL DN, Postow MA, Ibrahim N, Ludwig DL, et al
    An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
    Clin Cancer Res. 2016;22:5204-5210.
    PubMed     Abstract available


    August 2016
  124. WINKLER F, Osswald M, Blaes J, Liao Y, et al
    Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1327.2016.
    PubMed     Abstract available


    April 2016
  125. KREPLER C, Xiao M, Sproesser K, Brafford PA, et al
    Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Clin Cancer Res. 2016;22:1592-602.
    PubMed     Abstract available


    March 2016
  126. KOHLHAPP FJ, Kaufman HL
    Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Clin Cancer Res. 2016;22:1048-54.
    PubMed     Abstract available


    February 2016
  127. CHARYCH DH, Hoch U, Langowski JL, Lee SR, et al
    NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
    Clin Cancer Res. 2016;22:680-90.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: